Paper Details

  1. Home
  2. Paper Details

Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.

Author: AbergJudy A, AboulafiaDavid, BonillaHector, DimovaRositsa, DoonquahLeleka, DoveLorna, GalpinJeffrey, GlesbyMarshall J, HassaneinTarek, JacobsonIra M, JohnstonBarbara, LiuRuei-Chi, PearceDaniel, RodriguezJorge, TalalAndrew H, ZeremskiMarija

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

This study compared the effectiveness of intervening with hematologic growth factors versus dose reductions for managing treatment-induced hematologic disorders in HIV/HCV-coinfected patients receiving pegylated-interferon (PEG-IFN) and ribavirin (RBV).
Paper Details　
Original Abstract of the Article :
Pegylated-interferon (PEG-IFN) and ribavirin (RBV), current standard treatment for hepatitis C virus (HCV) infection, are frequently associated with neutropenia and anemia, leading to high treatment discontinuation rates in HIV/HCV-coinfected patients. Our objective was to compare the effectiveness ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/21876446

データ提供：米国国立医学図書館（NLM）

Managing Hematologic Side Effects in HIV/HCV Co-infection

Imagine a camel caravan traversing a harsh desert, its members facing various challenges along the way. This study explores treatment strategies for hematologic side effects in patients with HIV/hepatitis C virus (HCV) co-infection receiving pegylated-interferon (PEG-IFN) and ribavirin (RBV). It's like providing care and support to a caravan facing difficulties, seeking to optimize their health and well-being.

This research compares the effectiveness of hematologic growth factors versus dose reductions of standard HCV therapy for managing treatment-induced hematologic disorders in HIV/HCV-coinfected patients. It's like studying the different approaches to dealing with a sandstorm, analyzing the pros and cons of various strategies. The authors aim to determine the most effective approach for minimizing hematologic side effects and optimizing treatment outcomes.

Finding the Right Path: Managing Hematologic Side Effects

This study highlights the importance of managing hematologic side effects in HIV/HCV-coinfected patients receiving PEG-IFN and RBV. It underscores the need for personalized treatment approaches to minimize side effects and maximize treatment adherence. It's like a caravan leader, carefully assessing the needs of each camel and adjusting the journey accordingly to ensure the well-being of the entire group.

Navigating the Desert of Co-infection: A Journey of Care

This research emphasizes the complexity of managing HIV/HCV co-infection. It highlights the importance of addressing both the viral infections and the potential side effects of treatment. It's like a camel caravan facing multiple challenges, requiring a multifaceted approach to overcome obstacles and ensure a successful journey.

Dr. Camel's Conclusion

This study sheds light on the challenges of managing hematologic side effects in HIV/HCV co-infection. It's a reminder that even in the face of complex medical challenges, we can find solutions and improve the lives of those who need it most. It's a journey through the desert of co-infection, seeking to navigate the complexities and ensure a brighter future for patients.

Date :
  1. Date Completed 2011-12-07
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

21876446

DOI: Digital Object Identifier

NIHMS385437

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.